Clinical Trial Update: C-CAR168 CAR T Cell Therapy for Refractory Autoimmune Disease [Phase 1, Phase 2]

View source ↗

Summary

A Clinical Trial Update announcing AbelZeta's C-CAR168 CAR T cell therapy is in Phase 1/Phase 2 studies for refractory lupus nephritis, with sites not yet recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis

Drugs mentioned

• C-CAR168 CAR T Cell Therapy (C-CAR168 CAR T cells)

Snippet

Sponsor: AbelZeta Inc. | Conditions: Lupus Nephritis (LN) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING